CompletedNCT02936414
Berberine Added to Schizophrenia Treatment: A Placebo-Controlled Study
About this title
Read the official source — NCT02936414Medication studyAges 18–60China
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- TianjinSee all locations and recruitment
Study information
Study start dateJuly 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Tianjin Anding Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- China
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT02936414
- Official title
Show the full official title
Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tianjin
Questions about this study
Who is behind this study?
The study sponsor is Tianjin Anding Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Berberine and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
